Cabotegravir
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Cabotegravir |
| DrugBank ID | DB11751 |
| Brand Names (EU) | Apretude |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.45% |
Approved Indication (EMA)
Apretude is indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in high-risk adults and adolescents, weighing at least 35 kg (see sections 4.2, 4.4 and 5.1).
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | rheumatoid arthritis | 99.45% | DL |
| 2 | sclerosing cholangitis | 99.22% | DL |
| 3 | bronchitis | 99.19% | DL |
| 4 | colobomatous microphthalmia-rhizomelic dysplasia syndrome | 99.16% | DL |
| 5 | severe nonproliferative diabetic retinopathy | 99.03% | DL |
| 6 | brachydactyly-syndactyly syndrome | 98.67% | DL |
| 7 | diabetic retinopathy | 98.17% | DL |
| 8 | non-syndromic visceral malformation | 97.86% | DL |
| 9 | autosomal dominant familial hematuria-retinal arteriolar tortuosity-contractures syndrome | 97.83% | DL |
| 10 | brain small vessel disease 1 with or without ocular anomalies | 97.82% | DL |
| 11 | biliary atresia intrahepatic | 97.71% | DL |
| 12 | cholestasis | 97.46% | DL |
| 13 | colonic neoplasm | 97.38% | DL |
| 14 | Mirizzi syndrome | 97.30% | DL |
| 15 | diabetic nephropathy | 97.25% | DL |
| 16 | rectosigmoid junction neoplasm | 97.13% | DL |
| 17 | lipoma of colon | 97.09% | DL |
| 18 | colonic lymphangioma | 97.06% | DL |
| 19 | colon leiomyoma | 97.05% | DL |
| 20 | cavernous hemangioma of colon | 97.04% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.